Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 5Head & Neck 3Thoracic 2Endocrine 2CNS 2Other hematologic neoplasm 1NET 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Kidney Neoplasms 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 289enzalutamide 283Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 252Abiraterone Acetate 217Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 117Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 106cabozantinib 104atezolizumab 104Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytidine Triphosphate × Genitourinary × Clear all
NCT02086734 2018-10-02

Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma

Ludwig-Maximilians - University of Munich

Completed
60 enrolled
Genitourinary

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡